| Hazard Information | Back Directory | [Uses]
Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis[1][2]. | [in vivo]
Ziltivekimab (s.c., once every 4 weeks for a total of 24 weeks) can significantly reduce various biomarkers involved in stimulating the process of atherosclerosis and thrombosis (such as hsCRP (high-sensitivity C-reactive protein), fibrinogen, serum amyloid A, apolipoprotein A, secretory phospholipase A2, and lipoprotein (a)), which are also associated with systemic inflammation[4]. | [IC 50]
IL-6 | [References]
[1] Kristen L Nowak, et al. A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. Kidney360. 2020 Dec 4;2(2):224-235. DOI:10.34067/KID.0005862020
[2] Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021 Sep 28;117(11):e138-e140. DOI:10.1093/cvr/cvab231
[3] Gluba-Brzózka A, et al. Emerging Anti-Atherosclerotic Therapies. Int J Mol Sci. 2021 Nov 9;22(22):12109. DOI:10.3390/ijms222212109 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
|